Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 9, 2011, Pages 536-544

  Hennessy, S ^a   Leonard, C E ^a   Localio, A R ^a   Cohen, A ^a,b   Yang, W ^a   Cheung, L ^c   Strom, B L ^a,d   Herlim, M ^a   Feldman, H I ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute renal insufficiency; Aminoglycosides; Case control studies; Kidney failure, acute; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG UNDERDOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRESCRIPTION; RECOMMENDED DRUG DOSE; RISK FACTOR;

ACUTE KIDNEY INJURY; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACISTS; PHARMACY SERVICE, HOSPITAL;

EID: 80052971798     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201541     Document Type: Article

References (32)

1. Pippenger CE. Therapeutic drug monitoring assay development to improve efficacy and safety. Epilepsy Res. 2006; 68: 60-63. doi:10.1016/j.eplepsyres. 2005.09.022 PubMed (Pubitemid 43052783)
2. Bond CA, Raehl CL. 2006 national clinical pharmacy services survey: clinical pharmacy services, collaborative drug management, medication errors, and pharmacy technology. Pharmacotherapy. 2008; 28: 1-13. doi:10.1592/phco.28.1. 1 PubMed
3. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 2000; 30: 433-439. doi:10.1086/313692 PubMed (Pubitemid 30205284)
4. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003; 114: 194-198. doi:10.1016/S0002-9343(02)01476-6 PubMed (Pubitemid 36294004)
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41. doi:10.1159/000180580 PubMed
6. Urban AW, Craig WA. Daily dosage of aminoglycosides. Curr Clin Top Infect Dis. 1997; 17: 236-255. PubMed (Pubitemid 127674405)
7. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev. 1994; 13: 207-234. PubMed
8. Renal Disorders. In: Spector SA, Coppola CP, Bell RL (eds). Critical care clinical companion. Lippincott Williams & Wilkins; 2000. p. 486-505.
9. Koreny M, Karth GD, Geppert A, Neunteufl T, Priglinger U, Heinz G, Siostrzonek P. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med. 2002; 112: 115-119. doi:10.1016/S0002-9343(01)01070-1 PubMed (Pubitemid 34142542)
10. Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committe. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008; 23: 1569-1574. doi:10.1093/ndt/ gfn009 PubMed (Pubitemid 351767782)
11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Workgroup ADQI; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)Group. Crit Care. 2004; 8: 204-212. doi:10.1186/cc2872 PubMed
12. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol. 1982; 116: 547-553. PubMed
13. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984; 40: 63-75. doi:10.2307/2530744 PubMed
14. Zahar JR, Rioux C, Girou E, Hulin A, Sauve C, Bernier-Combes A, Brun-Buisson C, Lesprit P. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother. 2006; 58: 651-656. doi:10.1093/jac/dkl288 PubMed (Pubitemid 44288133)
15. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit. 1990; 12: 427-433. doi:10.1097/00007691-199009000-00004 PubMed (Pubitemid 20314034)
16. Pinilla J, Shafran S, Conly J. A utilization and cost-benifit analysis of an aminoglycoside kinetics monitoring service. Clin Invest Med. 1992; 15: 8-17. PubMed
17. Tierney MG, Braden LA. An evaluation of a pharmacy based aminoglycoside monitoring service. Can J Hosp Pharm. 1984; 37: 135-136, 143 PubMed
18. Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA, Roback JA, Lentino JR. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol. 1993; 4: 81-90. PubMed
19. Queener S. F. Systemic and CNS Toxicities of Antimicrobial Agents. In: Roos KL (ed). Principles of Neurologic Infectious Diseases. McGraw-Hill Professional; 2005. p. 475-516.
20. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM. 2002; 95: 291-297. doi:10.1093/qjmed/95.5.291 PubMed (Pubitemid 34537761)
21. Triggs E, Charles B. Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly. Clin Pharmacokinet. 1999; 37: 331-341. doi:10.2165/00003088-199937040-00004 PubMed (Pubitemid 29515697)
22. Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001; 21: 443-451. doi:10.1592/phco.21.5.443.34490 PubMed (Pubitemid 32275273)
23. Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis. 1986; 153: 1062-1068. doi:10.1093/infdis/153.6.1062 PubMed (Pubitemid 16086773)
24. Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol. 1987; 27: 216-220. PubMed (Pubitemid 18026905)
25. Kirkpatrick CM, Duffull SB, Begg EJ, Frampton C. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit. 2003; 25: 623-630. doi:10.1097/00007691-200310000-00012 PubMed (Pubitemid 37238897)
26. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984; 100: 352-357. PubMed (Pubitemid 14156536)
27. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993; 167: 173-179. doi:10.1093/infdis/167.1.173 PubMed (Pubitemid 23002853)
28. Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care. 2006; 10: 211. doi:10.1186/cc4907 PubMed
29. Hoste EA, Cruz DN, Davenport A, Mehta RL, Piccinni P, Tetta C, Viscovo G, Ronco C. The epidemiology of cardiac surgery-associated acute kidney injury. Int J Artif Organs. 2008; 31: 158-165. PubMed (Pubitemid 351425013)
30. Pancorbo S, Compty C, Heissler J. Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens. Biopharm Drug Dispos. 1982; 3: 83-88. doi:10.1002/bdd.2510030111 PubMed (Pubitemid 12111374)
31. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999; 43: 1549-1555. PubMed (Pubitemid 29331226)
32. Martin JE. Commentary: once-daily aminoglycoside dosing: where are we now? J Crit Care. 2003; 18: 113-114. doi:10.1053/jcrc.2003.50007 PubMed (Pubitemid 36759162)